INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAB4. A total of 29 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2019. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2019 | $8,572,000 | – | 8,630,000 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
HIGHBRIDGE CAPITAL MANAGEMENT LLC | 27,943,000 | $20,241,000 | 1.72% |
Worth Venture Partners, LLC | 1,569,000 | $1,134,000 | 0.56% |
Context Capital Management, LLC | 1,985,000 | $1,424,000 | 0.55% |
ADVENT CAPITAL MANAGEMENT /DE/ | 16,703,000 | $12,060,000 | 0.28% |
CSS LLC/IL | 6,825,000 | $4,985,000 | 0.28% |
SILVERBACK ASSET MANAGEMENT LLC | 1,500,000 | $1,095,000 | 0.27% |
Polar Asset Management Partners Inc. | 20,000,000 | $14,452,000 | 0.24% |
Senvest Management, LLC | 5,000,000 | $3,621,000 | 0.23% |
FARALLON CAPITAL MANAGEMENT LLC | 25,500,000 | $18,998,000 | 0.15% |
LINDEN ADVISORS LP | 12,755,000 | $9,258,000 | 0.15% |